---
canonical_name: Cnidium monnieri
alternate_names: Cnidii Fructus, Fructus Cnidii, She Chuang Zi, Monnier's Snowparsley, Selinum monnieri
canonical_topic: Cnidium monnieri for Health & Longevity
short_topic_lc: cnidium_monnieri
creation_date: 2026-0825-1350
creator_ai_fullname: Opus 5
ep_keywords: Osthole, Coumarins, Traditional Chinese Medicine, TCM Herbs
---

# Cnidium monnieri for Health & Longevity
<section id="top" markdown="1"></section>

Evidence Review created on 08/25/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 5

**Also known as:** Cnidii Fructus, Fructus Cnidii, She Chuang Zi, Monnier's Snowparsley, Selinum monnieri

  
## Motivation

<!-- Author's note: this Motivation section was written last, after every other section of this review was complete, so that it reflects the full scope of the material rather than an opening guess at it. -->

*Cnidium monnieri* is a flowering plant of the carrot family whose dried fruits have served as a medicine across East Asia for roughly two thousand years. Most of its activity is credited to a group of plant compounds called coumarins, above all one named osthole, which relaxes smooth muscle and shifts the balance between bone building and bone breakdown. It reaches Western buyers mostly as a capsule or standardized extract sold for male sexual function, and inside topical creams and washes for itchy skin.

Classical Chinese texts list the dried fruit chiefly for skin complaints and for weakness of the reproductive system, applied as a wash at least as often as it was swallowed. Laboratories have since taken the plant apart in detail, yet the enthusiasm that followed rests almost entirely on cell and animal work rather than on studies in people.

This review examines what is actually established: the biology behind the claims, how strong the evidence is for each proposed effect, the safety questions raised by the plant's light-sensitising compounds and its effects on liver enzymes, and the practical matters of dose, form, and product quality.

**[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)**

  
## Recommended Reading

High-level sources that discuss *Cnidium monnieri* or its principal coumarin, osthole, in substantial depth.

<!-- Author's note on the search: a real-time search was run on 17 August 2026 across the web and PubMed for high-level overview content on Cnidium monnieri / Cnidii Fructus / osthole, and separately, by name, for content from each of the six priority platforms (foundmyfitness.com, peterattiamd.com, hubermanlab.com, chriskresser.com, lifeextension.com, lifespan.io) using both general web search and domain-restricted search; the Life Extension on-site search for "cnidium" was additionally loaded directly and returned no matching article or product. No priority-platform content on this herb or on osthole exists. The five items below are narrative (non-systematic) reviews, each from a different journal, selected for breadth and for covering the chemistry, bone, and safety literatures respectively. -->

* [Phytochemistry, Ethnopharmacology, Pharmacokinetics and Toxicology of Cnidium monnieri (L.) Cusson](https://pubmed.ncbi.nlm.nih.gov/32028721/) - Sun et al., 2020

  The most complete single map of the plant's chemistry, cataloguing 429 constituents alongside traditional indications, absorption data, and the toxicology signals that shorter reviews leave out.

* [Osthole, a Coumarin from Cnidium monnieri: A Review on Its Pharmacology, Pharmacokinetics, Safety, and Innovative Drug Delivery Platforms](https://pubmed.ncbi.nlm.nih.gov/39327653/) - Lin et al., 2024

  Concentrates on the compound carrying most of the herb's activity and is unusually direct about its poor solubility, rapid clearance, and liver-toxicity signal.

* [Cnidii Fructus: A traditional Chinese medicine herb and source of antiosteoporotic drugs](https://pubmed.ncbi.nlm.nih.gov/38507853/) - Xu et al., 2024

  Traces the bone evidence from cell work through animal models into the small Chinese clinical literature, and names the signalling pathways linking the fruit's coumarins to bone formation.

* [Review on the protective activity of osthole against the pathogenesis of osteoporosis](https://pubmed.ncbi.nlm.nih.gov/37680712/) - Chen et al., 2023

  A mechanism-first companion to the bone literature, separating what osthole does to bone-building cells from what it does to bone-dissolving cells, while conceding that drug targets remain uncertain.

* [Pharmacological features of osthole](https://pubmed.ncbi.nlm.nih.gov/28513464/) - Jarząb et al., 2017

  A compact European account of osthole's anti-inflammatory, anticonvulsant, platelet, liver and nervous-system effects — breadth that the bone- and skin-focused reviews omit.

Note on priority sources: none of the six priority platforms has published anything on *Cnidium monnieri*, Cnidii Fructus, or osthole. The herb has no Western consumer profile outside sexual-performance products, so no priority-platform item could be listed without misrepresenting unrelated content. Note on source origin: almost the entire literature on this plant is produced by traditional-medicine research institutions in China, Korea, and Taiwan, several of which hold patents or institutional interests in the compounds they evaluate; this affiliation is a standing bias in favour of positive findings and is revisited in the Conclusion.

  
## Grokipedia

<!-- Author's note on the search: grokipedia.com was searched directly with the browser tool on 17 August 2026 for "Cnidium monnieri". The search returned five results, the first of which is a dedicated primary article at /page/Cnidium_monnieri. -->

[Cnidium monnieri](https://grokipedia.com/page/Cnidium_monnieri)

A dedicated encyclopedic entry covering the plant's botany, distribution, coumarin chemistry, and traditional medicinal applications, useful for orientation on nomenclature and geography before turning to the pharmacology literature.

  
## Examine

<!-- Author's note on the search: examine.com was searched directly on 17 August 2026 for "Cnidium monnieri". The site's own search endpoint returned a bot-detection interstitial, so the supplement page was retrieved directly; a dedicated, primary supplement page exists at /supplements/cnidium-monnieri/, written by Kamal Patel and last updated 28 August 2025. -->

[Cnidium monnieri](https://examine.com/supplements/cnidium-monnieri/)

The only independent consumer-facing evidence summary for this herb; it categorises the plant under men's health, describes the Viagra-like mechanism, and states that effects on testosterone and cognition remain unexplored.

  
## ConsumerLab

<!-- Author's note on the search: consumerlab.com was searched directly on 17 August 2026 for "Cnidium". Three results returned — one sexual-enhancer product review and two FDA recall notices on adulterated sexual-performance supplements — but none is a dedicated page for this herb, and the site notes the search term may appear only inside member-only report text. -->

No dedicated ConsumerLab article, product review, or ingredient page exists for *Cnidium monnieri*. The site has never tested this ingredient, so no independent potency or purity data on Cnidium products is available from it.

  
## Systematic Reviews

Systematic reviews and meta-analyses touching *Cnidium monnieri* or its principal coumarin, osthole.

<!-- Author's note on the search: PubMed was searched in real time on 17 August 2026 with "(Cnidium monnieri OR osthole) AND (systematic review[pt] OR meta-analysis[pt])", returning seven records; the five most relevant and most recent are listed, ranked by directness of relevance to the herb, then by recency and study size. -->

* [Effects of osthole on osteoporotic rats: a systematic review and meta-analysis](https://pubmed.ncbi.nlm.nih.gov/35980123/) - Wu et al., 2022

  Pools 13 randomized animal studies; the only quantitative synthesis of osthole for bone, and explicitly a preclinical, not clinical, result.

* [Topical Chinese herbal medicine in treating atopic dermatitis (eczema): A systematic review and meta-analysis with core herbs exploration](https://pubmed.ncbi.nlm.nih.gov/37328084/) - Wang et al., 2023

  Pools 20 randomized trials in people and identifies *Cnidium monnieri* as one of four core herbs in effective topical formulas.

* [Topical herbal medicine combined with pharmacotherapy for psoriasis: a systematic review and meta-analysis](https://pubmed.ncbi.nlm.nih.gov/23354931/) - Deng et al., 2013

  Eight randomized trials of multi-herb topical preparations added to standard therapy; notably, it reports adverse-event data rather than efficacy alone.

* [Coumarins and Their Derivatives in Animal Models of Asthma: A Systematic Review](https://pubmed.ncbi.nlm.nih.gov/41689296/) - Dos Santos et al., 2026

  Eighteen animal studies in which osthole and imperatorin are the most-studied coumarins, relaxing airway smooth muscle and lowering inflammatory signalling.

* [Effects of Plants on Osteogenic Differentiation and Mineralization of Periodontal Ligament Cells: A Systematic Review](https://pubmed.ncbi.nlm.nih.gov/26822584/) - Costa et al., 2016

  Places osthole among six plant-derived agents driving mineral deposition in human periodontal ligament cells, an independent cell-level check on the bone claims.

Coverage note on the trade-off: the claimed effects (bone, skin) each have a systematic review, and the psoriasis review above is the only one reporting pooled safety data. There is no systematic review or meta-analysis of the herb's principal risk — phototoxicity from its furanocoumarins or liver injury from osthole — so the risk side of the ledger is unrepresented at this evidence level and rests on primary toxicology work instead.

  
## Mechanism of Action

The fruit contains coumarins — osthole predominates, with imperatorin, bergapten, and xanthotoxin present in smaller amounts — plus a volatile oil. Osthole is a weak, non-selective phosphodiesterase inhibitor (phosphodiesterases are enzymes that destroy the internal signalling molecules cyclic GMP and cyclic AMP). By slowing that destruction, and by prompting the vessel lining to release nitric oxide (the gas that widens blood vessels), it relaxes smooth muscle in penile and arterial tissue; a hydrogen sulfide-dependent limb has also been described. In vessels it additionally blocks voltage-dependent calcium entry and opens potassium channels.

In bone, osthole activates Wnt/β-catenin and BMP-2/Smad signalling (two pathways instructing stem cells to become bone-forming osteoblasts) while suppressing RANKL-driven NF-κB and NFATc1 activation (the pathway maturing bone-dissolving osteoclasts). Its anti-itch action tracks with mast-cell stabilisation, and it is a non-electrophilic agonist at TRPA1 (an irritant-sensing ion channel).

Osthole is lipophilic and poorly water-soluble, moderately absorbed and rapidly cleared, distributing widely to liver, kidney, lung, spleen, and heart. It is oxidised by the liver enzymes CYP3A4, CYP1A2, and CYP2C9 (enzymes that break down most drugs). A competing mechanistic reading holds that the concentrations active in cell work exceed plausible blood levels, so much of the animal effect may belong to metabolites or to the whole-extract matrix rather than to osthole itself.

  
## Historical Context & Evolution

*Cnidium monnieri* entered the written record as she chuang zi in the Shennong Bencao Jing, the foundational Chinese materia medica compiled around the first to second century CE, where it is listed among the upper-grade agents. Its original indications were narrow and largely external: itching, weeping skin lesions, genital sores and discharge, and what the texts framed as cold and weakness of the reproductive organs. Preparation was as often a decocted wash, sitz bath, or fumigation as an internal decoction — a point frequently lost when the herb is marketed today purely as an oral capsule. It carries the same standing in Japanese, Korean, and Vietnamese practice, and remains an official drug of the Chinese Pharmacopoeia as Cnidii Fructus.

The pivot toward health optimization came from chemistry rather than tradition. Isolation of osthole and the [demonstration in 2000 that it relaxes rabbit erectile tissue](https://pubmed.ncbi.nlm.nih.gov/10799242/) by a phosphodiesterase-inhibiting, nitric-oxide-dependent route gave the traditional aphrodisiac claim a modern mechanism, arriving in the same period as sildenafil and inviting a "natural Viagra" framing that the herb's own human data have never supported. Bone research followed after 2005, when [osthole was shown to drive osteoblast differentiation](https://pubmed.ncbi.nlm.nih.gov/15956019/). Neither line has been overturned; both remain preclinical, and what changed over the last two decades is the depth of mechanistic detail, not the strength of the clinical case.

  
## Expected Benefits

### Medium 🟩 🟩

#### Reduced Itch and Eczema Severity from Topical Preparations

Traditional external use for itching now has human trial support, though indirectly. A [meta-analysis of 20 randomized controlled trials](https://pubmed.ncbi.nlm.nih.gov/37328084/) (RCT: participants assigned to treatment or control by chance) found topical Chinese herbal preparations outperformed placebo for atopic dermatitis (eczema) and identified *Cnidium monnieri* as one of four core herbs in the effective formulas. Mechanistic support comes from mast-cell stabilisation and reduced scratching in [animal work on the fruit extract](https://pubmed.ncbi.nlm.nih.gov/11853179/). The critical limitation: the herb was always one component of a multi-herb cream, never tested alone.

**Magnitude:** Symptom scores improved with a standardized mean difference of −0.35 (95% CI −0.59 to −0.10) versus placebo, and the response rate was 29% higher (RR 1.29, 95% CI 1.15–1.44). (SMD expresses effect size in standard deviations, CI is the range consistent with the data, and RR compares event rates between groups.)

### Low 🟩

#### Preservation of Bone Mineral Density

Osthole raises bone formation and suppresses bone resorption in ovariectomized and aged rodents. A [meta-analysis of 13 randomized animal studies](https://pubmed.ncbi.nlm.nih.gov/35980123/) found a large, consistent density gain, strongest under 10 mg/kg/day beyond two months. No human trial exists, which caps this at Low.

**Magnitude:** Bone mineral density rose with a standardized mean difference of 3.08 (95% CI 2.08–4.09) in rats; no human effect size exists.

#### Improved Erectile Response

Osthole relaxes penile erectile tissue by inhibiting phosphodiesterase and releasing nitric oxide, [demonstrated in isolated rabbit corpus cavernosum](https://pubmed.ncbi.nlm.nih.gov/10799242/), and [a 2025 rodent study](https://pubmed.ncbi.nlm.nih.gov/40220979/) added a hydrogen sulfide-dependent route and improved erectile responses in living rats. Human trials do not exist.

**Magnitude:** Concentration-dependent relaxation across 0.1–30 μM, with up to a threefold amplification of nitric-oxide-donor-induced relaxation at 30 μM in isolated tissue.

### Speculative 🟨

#### Topical Activity Against Dermatophyte Fungi

The aqueous fruit extract damages *Trichophyton rubrum*, the athlete's-foot fungus, by suppressing chitin synthase (the enzyme building its cell wall), [shown in cell work](https://pubmed.ncbi.nlm.nih.gov/34489895/). The basis is in vitro and traditional use only.

#### Blood Pressure Lowering

Oral fruit extract [lowered blood pressure in spontaneously hypertensive rats](https://pubmed.ncbi.nlm.nih.gov/38673809/), with osthole and imperatorin relaxing aortic rings at low micromolar concentrations. Rodent-only; no human blood pressure data exist for this herb.

#### Airway Relaxation in Asthma

A [systematic review of animal asthma models](https://pubmed.ncbi.nlm.nih.gov/41689296/) found osthole and imperatorin relax airway smooth muscle and reduce inflammatory signalling. The basis is entirely animal-model; no human respiratory trial has been attempted.

#### Antiproliferative and Anticancer Activity

Osthole slows proliferation and triggers cell death in tumour cell lines and xenografts, [per a narrative review](https://pubmed.ncbi.nlm.nih.gov/28513464/). The basis is cell and animal work only, at concentrations above achievable blood levels, with no human data.

#### Neuroprotection

Osthole reduces neuronal injury in models of stroke, epilepsy, and neurodegeneration through antioxidant and anti-inflammatory signalling, [per a review](https://pubmed.ncbi.nlm.nih.gov/37682453/). Basis is mechanistic and animal-model only; nothing in humans supports a cognitive or neurological claim.

#### Reduced Liver Fat and Insulin Resistance

Osthole [lowered liver fat and improved insulin resistance in rats fed a fattening diet](https://pubmed.ncbi.nlm.nih.gov/20717873/). Rodent-only; no human metabolic data exist, and the finding sits alongside the compound's own liver-toxicity signal.

  
## Benefit-Modifying Factors

* **CYP2C9 genotype:** Osthole is cleared partly by CYP2C9 (a liver enzyme that metabolises many drugs). Carriers of the reduced-function *2 and *3 variants clear it more slowly, plausibly raising exposure and effect from an identical dose, though this has not been tested clinically.

* **Baseline bone turnover markers:** Any bone benefit is most plausible where resorption is already elevated — high C-terminal telopeptide with low bone formation markers — since the compound's rodent effect is chiefly suppression of bone-dissolving cells rather than stimulation of already-normal bone formation.

* **Baseline vascular function:** The erectile and vasodilatory effects are largely endothelium-dependent, so a partially intact vessel lining is required. Where erectile dysfunction is predominantly neurogenic or from severe endothelial loss, the proposed mechanism has little to act on.

* **Sex:** All bone work used ovariectomized female rodents and all erectile work male animals, so the two headline claims rest on single-sex evidence. Whether the bone effect holds in men, or the vascular effect in women, is untested.

* **Pre-existing conditions:** Existing liver disease reduces the clearance of osthole and raises the relevance of its liver signal, while inflammatory skin disease is the setting in which the topical evidence was actually generated, making it the best-characterised context for benefit.

* **Age:** Rodent bone benefit appears in both ovariectomized and senile models, so older adults are the population where a bone effect is most plausible. Counterbalancing this, age-related decline in liver enzyme capacity and higher concurrent medication use raise interaction exposure.

  
## Potential Risks & Side Effects

### Medium 🟥 🟥

#### Phototoxic Skin Reactions from Furanocoumarins

The fruit contains bergapten (5-methoxypsoralen), xanthotoxin (8-methoxypsoralen), and imperatorin — furanocoumarins that bind DNA when activated by ultraviolet A light and are the active agents in medical psoralen light therapy. [A review of bergapten](https://pubmed.ncbi.nlm.nih.gov/34347307/) treats its phototoxicity as established, and [a review of furanocoumarin phototoxicity](https://pubmed.ncbi.nlm.nih.gov/39984024/) documents effects ranging from photoirritation through photogenotoxicity to photocarcinogenicity, dose-dependently. That second review was written by scientists employed by fragrance and cosmetics companies, whose employers benefit commercially from permissive exposure limits — a conflict of interest relevant to how protective its thresholds are.

**Magnitude:** Regulatory practice caps total furanocoumarins at 1 part per million in products intended for prolonged ultraviolet A exposure and 5 parts per million in other cosmetics; the literature reports no incidence figure for Cnidium products specifically, as furanocoumarin content is not declared on labels.

#### Undeclared Prescription Drugs in Cnidium-Containing Sexual-Performance Products

The herb's main commercial niche is the least-regulated corner of the supplement market. [Analysis of 150 sexual-performance supplements](https://pubmed.ncbi.nlm.nih.gov/25459948/) found most adulterated with phosphodiesterase-5 inhibitors (erectile dysfunction drugs) — sildenafil, tadalafil, vardenafil, or unapproved analogues — often above prescription doses. Osthole itself was detected in only a small minority. The clinical danger is a severe drop in blood pressure if such a product is taken alongside a nitrate. ConsumerLab's own recall notices for this category corroborate the pattern.

**Magnitude:** 61% of 150 products contained phosphodiesterase-5 inhibitors (27% approved drugs, 34% unapproved analogues), and 25% of the adulterated products exceeded the maximum recommended prescription dose.

### Low 🟥

#### Liver Injury from Osthole Metabolic Activation

Osthole is oxidised to a reactive quinone methide that binds cellular proteins; [mechanistic toxicology work](https://pubmed.ncbi.nlm.nih.gov/39793773/) traced this to CYP3A4 and CYP1A2, and blocking them protected liver cells. Rats develop raised liver transaminases (enzymes that leak from damaged liver cells). [Reviews](https://pubmed.ncbi.nlm.nih.gov/39327653/) name liver toxicity as osthole's principal safety concern.

**Magnitude:** Liver-cell toxicity rises with CYP3A4 and CYP1A2 activity and falls when they are inhibited; no human incidence figure exists, because no controlled human safety trial has been run.

#### Interference with Drugs Cleared by CYP2C9

Osthole competitively inhibits CYP2C9 in human liver preparations, [with inhibition constants varying by genotype](https://pubmed.ncbi.nlm.nih.gov/32238050/), and in rats it substantially prolongs the elimination of a CYP2C9 substrate. The practical exposure is to warfarin, phenytoin, and non-steroidal anti-inflammatory drugs, where prolonged clearance means accumulation.

**Magnitude:** Inhibition constants of 21.9, 18.1, and 13.1 μM for CYP2C9\*1, \*2, and \*3 respectively; in rats the half-life of a co-administered substrate rose from 8.4 to 11.4 hours and time-to-peak from 2.0 to 7.3 hours.

#### Local Irritation from Topical Preparations

Concentrated washes, baths, and creams containing the fruit can cause stinging, redness, and contact dermatitis on inflamed or broken skin — the exact surfaces on which the herb is traditionally used. The [pooled psoriasis trials](https://pubmed.ncbi.nlm.nih.gov/23354931/) reported no serious adverse events, but were too small and short to quantify irritation reliably.

**Magnitude:** No serious adverse events across eight pooled randomized trials of multi-herb topical preparations; the literature reports no irritation incidence rate, as none of the trials collected it systematically.

### Speculative 🟨

#### Additive Blood Pressure Lowering

The extract and its coumarins [lower blood pressure in rodents](https://pubmed.ncbi.nlm.nih.gov/38673809/) through vasodilation. Combined with antihypertensive medication or other vasodilators, additive blood pressure lowering is mechanistically plausible but has never been observed or measured in humans.

#### Hormonal and Reproductive Effects

Osthole [raised androgen levels in castrated rats](https://pubmed.ncbi.nlm.nih.gov/15551966/), and classical texts caution against the herb in certain reproductive states. Whether meaningful endocrine effects occur in intact humans is unknown; the basis is isolated animal reports.

#### Increased Bleeding Tendency from Platelet Inhibition

Osthole inhibits platelet aggregation, [per a review](https://pubmed.ncbi.nlm.nih.gov/28513464/), which could add to bleeding risk around surgery or alongside anticoagulants. The basis is in vitro and animal reports only; no human bleeding event has been described.

  
## Risk-Modifying Factors

* **CYP3A4 and CYP1A2 activity:** Because the liver signal depends on these enzymes creating the reactive metabolite, anything that induces them — carbamazepine, rifampicin, heavy tobacco use, charred meat — theoretically raises risk, while inhibitors such as ketoconazole reduce it.

* **CYP2C9 variants:** Carriers of the *2 and *3 reduced-function alleles show stronger inhibition of the enzyme by osthole, so a person already clearing warfarin or phenytoin slowly faces the largest proportional interaction.

* **Baseline liver enzymes:** Alanine and aspartate aminotransferase (the enzymes released when liver cells are damaged) define the reserve available. Values already at or above the upper reference limit remove the margin in which a further insult would go undetected.

* **Sex:** No sex-stratified safety data exist for this herb. Women are the only group with a formal contraindication, from the reproductive cautions in the classical literature and the absence of any pregnancy or lactation safety data.

* **Pre-existing conditions:** Liver disease, photosensitivity disorders such as lupus or porphyria, a history of light-sensitising drug reactions, and heavy sun or tanning-bed exposure each amplify one of the two principal hazards.

* **Age:** Older adults carry reduced liver reserve, greater cumulative ultraviolet skin damage, and far more concurrent prescriptions, so all three risk channels — liver, phototoxicity, interactions — widen simultaneously with age.

  
## Key Interactions & Contraindications

* **Warfarin and other CYP2C9 substrates (phenytoin, celecoxib, losartan, ibuprofen):** Caution. Osthole competitively inhibits CYP2C9, prolonging clearance and risking accumulation — over-anticoagulation and bleeding with warfarin. Mitigation: check the international normalised ratio (a clotting-time measure) within one to two weeks of starting or stopping.

* **CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin, grapefruit juice):** Caution. These reduce formation of the reactive liver metabolite yet raise total osthole exposure; net direction is unpredictable, so combined use warrants liver enzyme monitoring rather than dose adjustment.

* **CYP3A4 and CYP1A2 inducers (carbamazepine, rifampicin, St John's wort, tobacco smoke):** Caution. These accelerate formation of the reactive intermediate implicated in liver-cell toxicity. Mitigation: avoid the combination, or check liver enzymes at four to six weeks.

* **Nitrates and nitric oxide donors (nitroglycerin, isosorbide, amyl nitrite):** Absolute contraindication for any Cnidium-containing sexual-performance product, given the high rate of undeclared phosphodiesterase-5 inhibitors and the risk of profound, life-threatening hypotension (dangerously low blood pressure).

* **Antihypertensives and other vasodilators (amlodipine, doxazosin, hydralazine, sildenafil):** Caution. Additive blood pressure lowering is plausible from the vasodilatory coumarins. Mitigation: measure blood pressure at home during the first two weeks.

* **Photosensitising medications (amiodarone, doxycycline, thiazide diuretics, retinoids, methoxsalen):** Caution. Furanocoumarins add to the risk of severe sunburn and blistering. Mitigation: separate topical application from sun exposure by at least 24 hours.

* **Over-the-counter medications:** Caution with ibuprofen and naproxen, both CYP2C9 substrates, where clearance may slow; and with paracetamol, where a shared reliance on liver conjugation makes routine high-dose use inadvisable alongside the herb.

* **Supplements with additive effects:** Caution with St John's wort, bergamot, and grapefruit extracts, which add furanocoumarin load; with fish oil, ginkgo, and high-dose vitamin E, which add bleeding risk to the anticoagulant interaction; and with beetroot, citrulline, or arginine, which add vasodilation.

* **Horny goat weed, yohimbine, and tribulus:** Caution. These are co-formulated with Cnidium most often and carry the same adulteration exposure, so undeclared phosphodiesterase-5 inhibitor and hypotension risk compounds rather than diversifies. Mitigation: avoid multi-ingredient sexual-performance blends entirely.

* **Other interventions:** Caution alongside psoralen-ultraviolet-A phototherapy or medical tanning, where the added furanocoumarin load is directly additive to the treatment's own photosensitising mechanism.

**Populations who should avoid Cnidium monnieri:**

* Pregnant or breastfeeding women — no safety data at any dose, and classical texts carry explicit reproductive cautions
* People with active liver disease or transaminases above twice the upper limit of normal
* People with Child-Pugh Class B or C cirrhosis (advanced liver scarring), where clearance of the compound is substantially impaired
* People taking nitrates for angina, given the adulteration risk in this product category
* People with photosensitivity disorders — systemic lupus erythematosus, porphyria, xeroderma pigmentosum — or a personal history of melanoma
* People on warfarin who cannot access regular international normalised ratio testing
* Anyone within two weeks of scheduled surgery, given the antiplatelet signal and unpredictable drug metabolism

  
## Risk Mitigation Strategies

* **Choose osthole-standardized extracts over proprietary blends:** Blends marketed for sexual performance are the products found adulterated with prescription drugs; a single-herb extract stating osthole percentage removes most of that exposure.

* **Require third-party certification:** Products carrying NSF, USP, or Informed Choice marks are screened for undeclared pharmaceuticals, directly addressing the 61% adulteration rate found in the sexual-performance category.

* **Test topical preparations on a small skin patch first:** Apply to a 2 cm area of forearm for 48 hours before wider use, to detect the contact irritation that concentrated washes cause on inflamed skin.

* **Keep treated skin out of ultraviolet light:** Cover any area treated topically, or apply at night and wash before daylight, maintaining at least 24 hours' separation to prevent furanocoumarin-driven phototoxic burns.

* **Check liver enzymes at baseline and six weeks:** Alanine and aspartate aminotransferase detect the liver-cell injury seen in rodents; stopping on a doubling from baseline prevents progression to clinically significant hepatitis.

* **Start at the low end of the traditional range:** Beginning near 3 g of dried fruit equivalent daily rather than 15 g limits first-exposure severity for both the liver and the vasodilatory effects.

* **Avoid stacking furanocoumarin sources:** Excluding grapefruit, bergamot, and St John's wort during use prevents cumulative photosensitisation and compounding of the same liver enzyme interference.

* **Separate dosing from narrow-therapeutic-index drugs:** Taking the herb at least four hours from warfarin or phenytoin, and monitoring their levels, reduces the peak-concentration enzyme inhibition that drives accumulation.

  
## Therapeutic Protocol

* **Traditional oral dose:** Chinese Pharmacopoeia and classical practice use 3–10 g of dried fruit daily as a decoction; Examine cites 6–15 g of fruit or seed. No dose has been validated in a controlled human trial.

* **Extract equivalents:** Commercial 10:1 extracts are sold at 250–500 mg per capsule, and osthole-standardized extracts at 10–98% purity. A 500 mg 10:1 capsule approximates 5 g of raw fruit.

* **Traditional external protocol:** The dominant classical route is a decocted wash, sitz bath, or fumigation of 15–30 g of fruit in water, applied once or twice daily to affected skin — the form with the most human trial support.

* **Competing approaches:** Classical Chinese practice treats the fruit as a warming external agent within multi-herb formulas; the Western supplement approach isolates osthole as a standalone oral pro-erectile compound. Neither has outperformed the other in any comparison.

* **Attribution of approaches:** No named clinic or practitioner popularised the modern oral protocol. The isolated-osthole framing traces to the National Research Institute of Chinese Medicine, Taipei, whose 2000 erectile-tissue work supplied the mechanism.

* **Time of day:** Evening dosing suits the erectile and vasodilatory indication and keeps peak concentrations away from daytime ultraviolet exposure. Topical applications are best applied at night for the same reason.

* **Half-life:** Osthole is rapidly absorbed and rapidly cleared, with rodent elimination measured in a few hours and a single plasma peak; no human half-life has been published, so dosing intervals rest on tradition, not pharmacokinetics.

* **Single versus split dosing:** Rapid clearance argues for splitting the daily amount into two doses with food, which also improves absorption of this lipophilic, poorly water-soluble compound and blunts peak-driven enzyme inhibition.

* **Genetic polymorphisms:** CYP2C9\*2 and \*3 carriers, who clear osthole more slowly and show stronger enzyme inhibition, warrant the lower end of the range. CYP3A4 and CYP1A2 activity governs formation of the reactive liver metabolite.

* **Sex-based differences:** No dose has been separately studied in women, and the erectile literature is exclusively male. Reproductive cautions in the classical texts mean the herb is conventionally avoided by women of childbearing potential.

* **Age considerations:** Adults over 65 typically start at half the traditional dose, reflecting reduced liver reserve, higher concurrent prescription load, and the greater cumulative ultraviolet exposure that magnifies the phototoxicity concern.

* **Baseline biomarkers:** Liver transaminases determine eligibility, and bone turnover markers or blood pressure define the response being tracked. Without a measured baseline there is no way to attribute any subsequent change.

* **Pre-existing conditions:** Compromised liver function, anticoagulant therapy, and photosensitivity disorders each override dose selection entirely, moving the decision from how much to whether at all.

  
## Discontinuation & Cycling

* **Not a lifelong intervention:** Nothing in the evidence supports indefinite use. The oral compound has no validated long-term human safety record, so use is conventionally framed as time-limited rather than permanent.

* **Suggested duration:** Oral courses are usually run for 8–12 weeks against a defined endpoint, then stopped and reassessed. Topical courses typically run 2–4 weeks, matching the trial durations in the dermatology literature.

* **No known withdrawal effects:** No dependence, rebound, or withdrawal syndrome has been described for the fruit or for osthole in any animal or human report; abrupt cessation appears uneventful.

* **Tapering not required:** With no withdrawal signal and rapid clearance, no tapering protocol exists or appears necessary. Stopping outright is the norm in both classical and modern use.

* **Rationale for cycling:** Cycling has not been shown to preserve efficacy, since no tolerance has been documented. Its actual justification is cumulative exposure — periodic breaks limit total furanocoumarin and liver-metabolite load.

* **Stopping rules:** Discontinuation is warranted on any doubling of liver transaminases, any phototoxic skin reaction, unexplained bruising or bleeding, or symptomatic low blood pressure.

  
## Sourcing and Quality

* **Species authentication:** *Cnidium monnieri* is routinely confused with *Cnidium officinale* and *Ligusticum* species, which have different chemistry. Certificates of analysis should confirm the binomial and the plant part — dried ripe fruit, not root or aerial parts.

* **Osthole standardization:** Osthole content in raw fruit varies several-fold by growing region and harvest timing. Extracts standardized to a stated osthole percentage — commonly 10%, 30%, or 98% — are the only way to know the actual dose.

* **Third-party testing:** Given the [61% adulteration rate](https://pubmed.ncbi.nlm.nih.gov/25459948/) in the sexual-performance supplement category, an NSF, USP, Informed Choice, or Eurofins certificate screening for phosphodiesterase-5 inhibitors is the single most valuable quality signal for this ingredient.

* **Furanocoumarin disclosure:** No manufacturer currently declares bergapten or xanthotoxin content, though these drive the phototoxicity risk. Requesting the figure from the supplier is the only route to it, and a refusal is itself informative.

* **Contaminant screening:** Chinese-sourced medicinal fruits carry documented heavy metal and pesticide residue risk. Certificates should cover lead, cadmium, arsenic, mercury, and organochlorine residues against pharmacopoeial limits.

* **Brands and suppliers:** No major Western supplement brand carries a standardized single-herb product; supply is dominated by small importers such as Barlowe's Herbal Elixirs and by bulk ingredient houses. Compounding pharmacies working from Chinese Pharmacopoeia raw fruit are an alternative.

* **Form selection:** Whole dried fruit for decoction is the form with the longest use record and the least adulteration exposure; capsules of proprietary blends carry the most. Concentrated osthole extracts sit between the two.

  
## Practical Considerations

* **Time to effect:** Topical antipruritic effects in the dermatology trials appeared within 1–2 weeks. For oral use, no human time-course exists; rodent bone effects required more than two months, so an equivalent trial would be a quarter at minimum.

* **Common pitfall — treating it as a proven erectile agent:** The "natural Viagra" framing rests on isolated rabbit tissue and rat studies. Buying it for that purpose usually means buying a blend, which is the highest-adulteration product category.

* **Common pitfall — ignoring the traditional route:** The human evidence is topical, yet the market sells capsules. Taking it orally while expecting the skin benefits documented in trials mismatches the route to the evidence.

* **Common pitfall — sun exposure after topical use:** Applying a Cnidium wash and then going outdoors reproduces the exact conditions of psoralen light therapy, and severe burns are the predictable result.

* **Regulatory status:** Sold in the United States as a dietary supplement, meaning the Food and Drug Administration reviews neither efficacy nor safety before marketing. It is an official pharmacopoeial drug in China and a regulated herbal medicine in Korea and Japan.

* **Cost and accessibility:** Inexpensive and widely available online — raw fruit and 10:1 extracts both cost a few cents per daily dose — so cost is not a barrier and does not weigh in the risk-benefit calculation.

* **Structural incentives:** Its comparators, generic sildenafil and generic bisphosphonates, are already cheap and reimbursed, so insurers have no incentive to fund a herbal substitute. Research funding sits almost entirely with Chinese traditional-medicine institutes, biasing guideline attention toward the traditional framing.

  
## Interaction with Foundational Habits

* **Sleep:** Indirect and mostly neutral. No sedative or stimulant effect has been reported at traditional doses, and osthole's anticonvulsant and neuroprotective animal signals have not translated into any measured sleep change. Practical point: evening dosing is preferred for reasons of ultraviolet avoidance rather than any effect on sleep architecture.

* **Nutrition:** Potentiating on absorption, blunting on interactions. Osthole is lipophilic and poorly water-soluble, so taking it with a fat-containing meal improves absorption. Grapefruit, bergamot, and celery should be excluded, as they add furanocoumarin load and compound the same liver enzyme interference the herb already exerts.

* **Exercise:** No direct interaction, with a plausible indirect one. Osthole promotes bone formation in loaded rodent bone, and mechanical loading drives the same Wnt/β-catenin pathway, so resistance and impact training is the logical partner for any bone-directed use. No blunting of muscle hypertrophy has been reported.

* **Stress management:** Indirect and unquantified. No effect on cortisol or the stress axis has been measured for the fruit or for osthole in humans. The only practical link runs the other way: sustained psychological stress raises liver enzyme burden and worsens inflammatory skin disease, the setting where the herb's evidence is strongest.

  
## Monitoring Protocol & Defining Success

Before starting, a liver panel establishes whether there is any reserve to spare, since liver-cell injury is the principal internal hazard, and it defines the baseline against which any later change is judged. Seated blood pressure and, where the goal is bone, a bone turnover panel with vitamin D complete the picture. Anyone on warfarin needs a documented clotting time before the first dose. Ongoing monitoring follows a simple cadence: liver enzymes and blood pressure at 6 weeks, then at 12 weeks; clotting time at 1 and 4 weeks for those anticoagulated; bone turnover markers no sooner than 6 months, since they move too slowly to read earlier. Beyond that, testing every 6–12 months suffices for continued use.

| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|---|---|---|---|
| ALT | <25 U/L (men), <20 U/L (women) | Detects liver-cell injury, the main internal hazard | ALT = alanine aminotransferase, an enzyme released when liver cells are damaged. Conventional labs flag only above 40–55 U/L, far above the functional target. Fasting not required |
| AST | <25 U/L | Confirms an ALT rise is hepatic rather than muscular | AST = aspartate aminotransferase. Conventional labs flag only above 35–40 U/L. Pair with ALT and creatine kinase; recent intense exercise raises it independently of the liver |
| GGT | <20 U/L (men), <15 U/L (women) | Most sensitive early marker of drug-induced liver stress | GGT = gamma-glutamyl transferase. Conventional upper limits reach 50–70 U/L. Alcohol within 72 hours confounds the result |
| INR | 2.0–3.0 if anticoagulated; otherwise 0.9–1.1 | Catches over-anticoagulation from CYP2C9 inhibition | INR = international normalised ratio, a standardised clotting time. Only relevant on warfarin; check at 1 and 4 weeks after any change |
| 25-hydroxyvitamin D | 40–60 ng/mL | Any bone effect is contingent on adequate vitamin D | Conventional labs accept 30 ng/mL as sufficient. Draw at a consistent season; levels fall in winter |
| Serum CTX | 0.20–0.40 ng/mL | Tracks bone resorption, the process osthole suppresses in rodents | CTX = C-terminal telopeptide of type I collagen. Requires an early-morning fasted draw; it varies over 20% across the day |
| P1NP | 25–50 μg/L | Tracks bone formation, the other half of the bone claim | P1NP = procollagen type I N-terminal propeptide. Best paired with CTX on the same draw; interpret the two together, not separately |
| Seated blood pressure | 110–125 / 70–80 mmHg | Detects additive hypotension from the vasodilatory coumarins | Home cuff, seated 5 minutes, morning and evening. Track the trend across two weeks, not single readings |

Qualitative markers worth tracking alongside the laboratory values:

* Skin itch intensity and lesion extent, scored weekly on a simple 0–10 scale where the goal is dermatological
* Any stinging, redness, or blistering at a topical application site, particularly after daylight exposure
* Erectile firmness and consistency, where that is the goal, recorded as a weekly rather than per-occasion impression
* Energy levels, appetite, and right-upper-quadrant discomfort, which together precede laboratory evidence of liver strain
* Unexplained bruising, prolonged bleeding from minor cuts, or dark stools, which flag the anticoagulant interaction
* Light-headedness on standing, the earliest symptom of additive blood pressure lowering

  
## Emerging Research

* **Cervical papillomavirus clearance trial:** [NCT06705322](https://clinicaltrials.gov/study/NCT06705322), a Phase 2 single-arm multicentre study at Fudan University enrolling 79 women, tests a *Cnidium monnieri*-based oral formula for clearance of persistent high-risk human papillomavirus, with clearance at 6 months as the primary endpoint.

* **Psoriasis cream trial:** [NCT07410793](https://clinicaltrials.gov/study/NCT07410793), a Phase 2 randomized trial at Mae Fah Luang University in 28 participants, compares a Chinese herbal cream containing *Cnidium monnieri* against calcipotriol, both with acupuncture, using severity scores at 8 weeks.

* **Liver toxicity mechanism:** Work by [Liu et al., 2025](https://pubmed.ncbi.nlm.nih.gov/39793773/) identifying a reactive quinone methide metabolite could weaken the case for oral use considerably if human liver enzyme activity proves to generate it at realistic doses.

* **Bioavailability engineering:** [Lin et al., 2024](https://pubmed.ncbi.nlm.nih.gov/39327653/) catalogue nanoparticle and micelle delivery platforms designed to overcome osthole's poor solubility. Success would make the high concentrations used in cell studies achievable, testing whether those effects survive translation.

* **Hydrogen sulfide pathway:** [Alan-Albayrak et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40220979/) propose a hydrogen sulfide route to erectile improvement, positioning osthole for cases where standard phosphodiesterase-5 inhibitors fail. It remains a rodent finding awaiting any human test.

* **The unclosed bone gap:** [Wu et al., 2022](https://pubmed.ncbi.nlm.nih.gov/35980123/) called for clinical studies of osthole in osteoporosis. None has registered since, and a null human trial would substantially undercut the largest body of preclinical evidence supporting this herb.

  
## Conclusion

*Cnidium monnieri* is a dried fruit with a two-thousand-year record in East Asian medicine, used mainly as a wash for itchy skin and as an internal remedy for reproductive complaints. Its chemistry is well described, and its main compound has a coherent, plausible story behind each of its two headline claims: relaxing smooth muscle in erectile tissue, and shifting the balance of bone building and breakdown.

The gap between that story and proof in people is wide. The only human trial evidence concerns creams and washes for eczema and psoriasis, where the herb was one ingredient among several, and where the improvement was modest. Everything else — bone, erections, blood pressure, liver fat, tumours, nerves — comes from cells and rodents. Against that sits a real safety ledger: compounds that make skin burn in sunlight, a liver signal traced to a reactive breakdown product, interference with the clearance of common medications, and a supplement market — the sexual-performance category that is this herb's main commercial niche — in which most products tested were found to contain undeclared prescription drugs.

The evidence base is also narrow in origin. Nearly all of it comes from traditional-medicine research institutions with an interest in favourable results, and the one review setting exposure limits for the light-sensitising compounds was written by cosmetics-industry scientists whose employers gain from permissive thresholds. For someone weighing this deliberately, the topical use is the part standing on human data; the oral use remains an interesting hypothesis carrying quantified risks.

**[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**